** Drugmaker BioMarin Pharmaceutical's BMRN.O shares rise ~1.8% to $68.25 premarket
** Oppenheimer upgrades BMRN to "outperform" from "perform" rating
** Brokerage says new management's focus on operational efficiencies, cost reduction and return on R&D investments will boost BMRN's revenue growth
** Twenty-three of 29 brokerages rate the stock "buy" or higher, 6 "hold"; their median PT is $95 - data compiled by LSEG
** As of last close, stock up ~3.8% YTD
(Reporting by Prakhar Srivastava in Bengaluru)
((Prakhar.srivastava2@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。